Answers are grounded in this paper and cite their sources.
• Use of Indocyanine green (ICG) as a tracer for sentinel lymph node biopsy in patients with node negative early breast cancer. • Detection of ICG fluorescence using a camera with wavelength filters. • Comparable sentinel lymph node detection rates between ICG and radioisotope. • Low axillary recurrence rates after sentinel lymph node biopsy using ICG. Sentinel lymph node biopsy (SLNB) is an established standard technique for staging the axilla in clinically node-negative breast cancer patients. This study evaluates the efficacy of a dual tracer technique combining Indocyanine Green (ICG) fluorescence and blue dye for SLNB in early breast cancer patients at a single institution (Perth Royal Infirmary, Scotland). Over an eight-month period, 139 patients with clinically node-negative invasive breast cancer underwent SLNB, achieving a sentinel lymph node identification rate of 98.5 %. Among the identified nodes, a node positivity rate of 19.7 % was observed. With a median follow-up of 42 months, axillary recurrence was recorded in only 0.9 % of patients, alongside local and distant recurrences of 1.8 % and 5.5 %, respectively. The findings suggest that the ICG and blue dye technique maintains a low axillary recurrence rate comparable to traditional methods, while also addressing logistical challenges posed by the COVID-19 pandemic. This technique offers a promising alternative to radioisotope-based methods and opens new possible routes for non-radioactive axillary staging techniques. Further long-term outcomes are anticipated as the use of ICG as a sole tracer is integrated into routine practice.
No takes yet. Share an insight, caveat, or question.
Kanitkar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: